Acura Pharmaceuticals (ACUR) 10-K2021 FY Annual report

Filed: 30 Jun 23, 1:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: attrition, ay, bid, blockade, contradictory, corroborated, Embedded, ERC, exit, fashion, fifteen, hand, hereunder, hierarchy, IL, illiquid, implicit, inflow, Inline, maker, marked, negate, orderly, outflow, overdue, piece, plasma, room, sophisticated, stability, Taxpayer, temperature, unexercised, unobservable, wage

Removed: amounted, AP, applied, ASC, averse, Bayer, borrowing, calculate, Codification, community, consortium, disclose, disrupt, duration, Eaglet, element, EPS, explore, extinguishment, fact, formed, imputed, IP, Jersey, joint, lender, lent, minimal, modification, noting, Patheon, penny, PIPE, polysorb, premium, reluctant, replacing, Roth, seasoned, seize, SPA, steady, steering, Subordination, surfactant, tangible, terminating, unamortized, unconsolidated, Vivo

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ACUR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Acura Pharmaceuticals, Inc.

Palatine, Illinois

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-256677, 333-221645, 333-213017, 333-195612, and 333-151620) of Acura Pharmaceuticals, Inc. of our report dated June 30, 2023, relating to the consolidated financial statements which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

/s/ BDO USA, LLP

Chicago, Illinois

June 30, 2023

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.